CliffBio
biologic

Pasatru

garetosmab-grts

Loss of exclusivityAugust 2038projected — 12-year biologic exclusivity estimate
CompanyRegeneron Pharmaceuticals, Inc.

Drug detail

Brand namePasatru
Active ingredientgaretosmab-grts
Strength300MG/5ML (60MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2026
Marketing statusRx

More from Regeneron Pharmaceuticals, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Pasatru patent cliff — loss of exclusivity August 2038 | CliffBio